Analysts at UBS lower price target on the firm which makes medical devices to A$240 from A$260
** Brokerage downgrades rating on stock to "Sell" from "neutral"
** UBS expects Cochlear's implant sales to be possibly impacted if Moderna MRNA.O makes a vaccine against cytomegalovirus (CMV) infection
** Stock hits lowest since Jan.24
** Three of 16 analysts rate the stock "Buy", seven "Hold" and six "sell" or lower; their median PT is A$260.88 – LSEG data
** Stock has risen 3.3% this year, as of last close
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$319.14 |
Change
2.140(0.68%) |
Mkt cap ! $20.89B | |||
| Open | High | Low | Value | Volume |
| $317.80 | $319.56 | $315.50 | $17.87M | 56.19K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 42 | $319.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $319.22 | 20 | 6 |
View Market Depth
| Last trade - 15.37pm 29/07/2025 (20 minute delay) ? |
| COH (ASX) Chart |